Actively Recruiting
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Led by European Institute of Oncology · Updated on 2026-03-24
125
Participants Needed
1
Research Sites
314 weeks
Total Duration
On this page
Sponsors
E
European Institute of Oncology
Lead Sponsor
P
Pfizer
Collaborating Sponsor
AI-Summary
What this Trial Is About
Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration
CONDITIONS
Official Title
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing.
- Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.
You will not qualify if you...
- Unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
European Institute of oncology
Milan, Italy, Italy, 20141
Actively Recruiting
Research Team
E
Elena Guerini Rocco, MD
CONTACT
F
francesca lombardi, biologist
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here